| (Values in U.S. Thousands) | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 |
| Sales | 85,670 | 80,820 | 100,000 | 0 | 0 |
| Sales Growth | +6.00% | -19.18% | unch | unch | unch |
| Net Income | -13,930 | -61,090 | -21,170 | 7,130 | -550 |
| Net Income Growth | +77.20% | -188.57% | -396.91% | +1,396.36% | unch |
Lakeshore Biopharma Ltd (LSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
LakeShore Biopharma is a biopharmaceutical company. It involved in discovering, developing, manufacturing and delivering vaccines and therapeutic biologics for infectious diseases and cancer. The company operates primarily in China, the United States, Singapore and the Philippines. LakeShore Biopharma, formerly known as YS Biopharma, is based in GAITHERSBURG, Md.